CTNNB1 and prostate carcinoma: We have identified targets such as AKT1, TNF, IL6, STAT3, and CTNNB1 in Osthole’s inhibition of prostate cancer, along with pathways including the TNF signaling pathway, the Interleukin-6-17 (IL-6-17) signaling pathway, and the prolactin signaling pathway.